Literature DB >> 31628584

Tissue Fixation Conditions for p16 Immunohistochemistry and Human Papillomavirus RNA In Situ Hybridization in Oropharyngeal Squamous Cell Carcinoma.

James S Lewis1,2, Shira B Barnett3, Kyle Mannion4, Mitra Mehrad3,4.   

Abstract

Human papillomavirus (HPV) has become a critical prognostic biomarker in oropharyngeal squamous cell carcinoma (OPSCC). While retrospective studies suggest that p16 immunohistochemistry and even HPV RNA in situ hybridization work well on tissues and tumors from a variety of labs and various fixation conditions, no formal study of fixation conditions has been performed to date. We took surgically resected specimens from three p16 and HPV RNA in situ hybridization positive OPSCC patients, divided their fresh tumors into small pieces, and varied the time to formalin fixation as 1, 3, 6, 24, and 48 h. Tumors were either held moistened at room temperature or were refrigerated. After fixation and processing, routine hematoxylin and eosin slides were generated and p16 immunohistochemistry and RNA in situ hybridization performed. All three tumors were nonkeratinizing and had strong and diffuse p16 expression at immediate fixation, which, surprisingly, remained positive for all fixation times and conditions and despite significant degeneration at the later points for two of the patients while for one, the nuclear signal dropped out of most cells at early and mid time points, particularly at room temperature, causing false negatives. HPV RNA in situ hybridization stayed positive in all specimens up to 48 h of cold ischemic time refrigerated and even at room temperature, except for overtly autolyzed tumor regions. These findings help to establish that, at least for standard nonkeratinizing, p16 and HPV RNA strongly positive OPSCC patients, and using the most common tests in clinical practice, relatively lenient time to fixation may be acceptable if it cannot be avoided. However, for some patients, p16 immunohistochemistry may be sensitive to signal loss with autolysis. HPV RNA in situ hybridization, in particular, seems remarkably resistant to pretest cold ischemic times.

Entities:  

Keywords:  Fixation; Human papillomavirus; In situ hybridization; Oropharyngeal; Squamous cell carcinoma; p16 immunohistochemistry

Mesh:

Substances:

Year:  2019        PMID: 31628584      PMCID: PMC7413959          DOI: 10.1007/s12105-019-01090-6

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  26 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

3.  Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan.

Authors:  Takatsugu Mizumachi; Akihiro Homma; Tomohiro Sakashita; Satoshi Kano; Hiromitsu Hatakeyama; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2017-03-07       Impact factor: 3.402

4.  Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.

Authors:  James S Lewis; Beth Beadle; Justin A Bishop; Rebecca D Chernock; Carol Colasacco; Christina Lacchetti; Joel Todd Moncur; James W Rocco; Mary R Schwartz; Raja R Seethala; Nicole E Thomas; William H Westra; William C Faquin
Journal:  Arch Pathol Lab Med       Date:  2017-12-18       Impact factor: 5.534

Review 5.  Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 6.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Authors:  Maura L Gillison; Anil K Chaturvedi; William F Anderson; Carole Fakhry
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

7.  Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.

Authors:  William M Lydiatt; Snehal G Patel; Brian O'Sullivan; Margaret S Brandwein; John A Ridge; Jocelyn C Migliacci; Ashley M Loomis; Jatin P Shah
Journal:  CA Cancer J Clin       Date:  2017-01-27       Impact factor: 508.702

8.  De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.

Authors:  Liam Masterson; Daniel Moualed; Zi Wei Liu; James E F Howard; Raghav C Dwivedi; James R Tysome; Richard Benson; Jane C Sterling; Holger Sudhoff; Piyush Jani; Peter K C Goon
Journal:  Eur J Cancer       Date:  2014-08-01       Impact factor: 9.162

Review 9.  Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.

Authors:  Parish P Sedghizadeh; William D Billington; Dain Paxton; Rabeh Ebeed; Susan Mahabady; Glenn T Clark; Reyes Enciso
Journal:  Oral Oncol       Date:  2016-01-18       Impact factor: 5.337

10.  Prognostic Impact of AJCC/UICC 8th Edition New Staging Rules in Oropharyngeal Squamous Cell Carcinoma.

Authors:  Nora Würdemann; Steffen Wagner; Shachi Jenny Sharma; Elena-Sophie Prigge; Miriam Reuschenbach; Stefan Gattenlöhner; Jens Peter Klussmann; Claus Wittekindt
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.